Adial Pharmaceuticals
ADIL
23 hedge funds and large institutions have $877K invested in Adial Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
158% more capital inflows, than outflows
Capital inflows: $536K | Capital outflows: $208K
10% more funds holding
Funds holding: 21 → 23 (+2)
2.55% more ownership
Funds ownership: 6.26% → 8.81% (+2.5%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manchester Capital Management
Manchester,
Vermont
|
+$466K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.9K |
| 3 |
Two Sigma Securities
New York
|
+$6.79K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.82K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$5.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$107K |
| 2 |
Renaissance Technologies
New York
|
-$58.6K |
| 3 |
Virtu Financial
New York
|
-$16K |
| 4 |
Two Sigma Investments
New York
|
-$15.8K |
| 5 |
HRT Financial
New York
|
-$6K |
ADIL Hedge Fund Activity: Q1 2023 in Review
23 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2023, worth a combined $877K — up 144% from $359K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ADIL positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Manchester Capital Management, opening a new position worth an estimated $466K. The largest seller was Vanguard Group, cutting an estimated $107K.
- 23 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2023, up from 21 in Q4 2022.
- Funds reported $877K of Adial Pharmaceuticals stock for Q1 2023, up 144% quarter-over-quarter.
- 3 funds opened new Adial Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest Adial Pharmaceuticals buyer in Q1 2023 was Manchester Capital Management, an estimated $466K added.
- The largest Adial Pharmaceuticals seller in Q1 2023 was Vanguard Group, an estimated $107K sold.
Based on aggregated 13F filings for Q1 2023.